CRISPR Therapeutics AG (CRSP) Cash from Financing Activities (2015 - 2026)

CRISPR Therapeutics AG has reported Cash from Financing Activities for 12 years, with the latest figure at $591.9 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 5490.37% year-over-year to $591.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 2649.46% YoY) and the FY2025 annual result came in at $426.0 million, up 28.33% from the prior year.
• Cash from Financing Activities advanced to $591.9 million in Q1 2026 per CRSP's latest filing, from $116.4 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $591.9 million in Q1 2026 and troughed at -$466000.0 in Q2 2024.
• A 5-year average of $85.4 million and a median of $10.6 million in 2022 frame the typical range for Cash from Financing Activities.
• The widest YoY moves for Cash from Financing Activities: up 5561.25% in 2024, down 102.78% in 2024.
• Over 5 years, Cash from Financing Activities stood at $2.5 million in 2022, then jumped by 1471.39% to $38.9 million in 2023, then plunged by 56.66% to $16.9 million in 2024, then soared by 589.82% to $116.4 million in 2025, then soared by 408.45% to $591.9 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $591.9 million, $116.4 million, and $296.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.